| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Profit before tax | 0.6 | -2.4 |
| Net income | 0.6 | -2.4 |
| EPS (diluted, $ a share) | $0.10 | $-0.39 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: XCUR. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Exicure, Inc.: key numbers
- Share price
- $1.08Close, Nov 17
- Market cap
- $6.55M
- Shares outstanding
- 6.55MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Exicure, Inc.
All →Exicure Partnership with NeuroQ Biologics Inc. and Laonz Co., Ltd. Worth $500K
Exicure entered into a Strategic Business Expansion and Investment Agreement to acquire a 20% to 100% equity stake in NeuroQ Biologics through a share exchange with Laonz Co. The partnership focuses on commercializing X-CUE, an augmented-reality smart-glasses technology for Parkinson's disease patients, with Exicure committing up to $0.5 million in development funding.
- Value
- $500K
- Counterparty
- NeuroQ Biologics Inc. and Laonz Co., Ltd.
Exicure Divestiture to GPCRT Inc. for $4.8M
Exicure, Inc. and its subsidiary GPCR USA entered into a definitive agreement to sell their GPC-100 (burixafor) program assets to South Korea-based GPCRT Inc. for approximately $4.8 million (KRW 6.5 billion) in cash. The divestiture includes intellectual property, clinical data, and the assignment of a 2025 license agreement, with the buyer assuming future milestone and royalty obligations. The sale is part of Exicure's ongoing evaluation of strategic alternatives to maximize stockholder value and strengthen its financial position.
- Value
- $4.8M
- Counterparty
- GPCRT Inc.
Exicure Nasdaq/NYSE Compliance Notice
Exicure, Inc. received an extension from Nasdaq until December 2, 2026, to regain compliance with the minimum $2.5 million stockholders' equity requirement. The company originally received a deficiency notice on June 5, 2026, and must now complete compliance initiatives to avoid potential delisting. This extension provides the company additional time to strengthen its financial position and meet continued listing standards.
- Counterparty
- Nasdaq
- Term
- through Dec 2, 2026